Newsletter · 2026-09-18 · Ashutosh Agarwal

Healthcare Becomes the Anti-AI Trade as Biotech Runs - Healthcare Podcast Weekly Digest - Week of September 18, 2026

Healthcare Podcast Weekly Digest for the week of September 18, 2026. As nervous money rotates out of expensive AI and tech names, the week's podcasts framed healthcare as the 'anti-AI trade' and biotech (XBI up about 70% in a year) as the market's smart-money hideout, while the sector split between drug makers paying up for unproven pipelines and insurers trading at a discount amid hospital lawsuits and contract deadlines.

Healthcare Podcast Weekly Digest

Week of September 18, 2026: Healthcare Becomes the Anti-AI Trade as Biotech Runs

The Week in One Breath

This was the week healthcare stopped being the boring corner of the market and started looking like the smart-money hideout.

The big idea running through almost every investing podcast: as people get nervous about how expensive AI and tech stocks have become, money is quietly rotating into healthcare, and biotech in particular has been on a tear. On WSJ's Take On the Week (Sep 13), Wall Street Journal columnist David Wehner put a number on it:

"XBI, which is the big biotech ETF, is up about 70% over the past year versus about 20% for the S&P 500. So that's a really significant outperformance."

His explanation is the story of the whole sector right now. Investors panicked when President Trump took office again with RFK Jr. as health secretary and talk of forcing U.S. drug prices down to European levels (a policy called "most favored nation"). Then, in late 2025, Trump signed a wave of truce agreements with pharma CEOs, starting with Pfizer's Albert Bourla, and the fear lifted. As Wehner put it, "Wall Street's going, like, okay, the field's clear." Add the AI-rotation money on top, and you get a rally.

But under that headline, the sector split cleanly in two this week, and the two halves did opposite things. One half (drug makers like Vertex and Eli Lilly) went shopping for expensive, unproven pipelines. The other half (insurers and pharmacy giants like UnitedHealth and CVS) spent the week getting sued by hospitals and staring down contract deadlines. The market is paying up for the first group and demanding a discount from the second, and the podcasts spent real time arguing over whether that gap makes sense.

Below: who said what, the companies everyone's talking about, the debates worth watching, and the calendar for the days ahead.

Key People This Week

Hot Topics: The Companies and Drugs Everyone Talked About

GLP-1 Weight-Loss Drugs (Eli Lilly vs. Novo Nordisk), Still the Center of Gravity

The obesity-drug race remained the single most-discussed subject in healthcare, and this week the numbers kept tilting toward Eli Lilly ($LLY):

• Lilly's 2026 revenue guidance sits at a record $85–87 billion. Its injectable Zepbound holds 60.1% of the U.S. obesity market, ahead of Novo's Wegovy.
• Its new daily pill, orforglipron (brand name Foundayo), the first once-a-day oral weight-loss drug you can take without food restrictions, has already reached roughly 47,500 prescriptions since its April 1 approval.
• The eye-catcher for the future: Lilly's experimental triple-hormone shot retatrutide delivered 28.3% weight loss (about 70 pounds) at 80 weeks in a large Phase 3 trial, a level that starts to rival surgery. An FDA filing is expected late 2026.

Novo Nordisk ($NVO) is the mirror image: cheaper (about 13x forward earnings versus Lilly's 24–31x) because its pipeline stumbled. Its next-generation combo CagriSema failed to beat Lilly's Zepbound head-to-head, missing Novo's own 25% weight-loss target. The market is treating Lilly as the winner and Novo as the value/turnaround bet.

A skeptical voice worth hearing: on The Bio Report (Sep 16), Wave Life Sciences science chief Eric Ingelson argued these drugs, for all their power, leave a big opening: a large share of the weight lost is muscle, side effects are common, and most people stop taking them within a year. Wave is developing an RNA-based drug (targeting a protein called activin E) that in an early trial cut visceral (belly) fat by 14% from a single dose. Translation: even inside the GLP-1 gold rush, companies are racing to build the "next thing" that fixes the shortcomings.

And a real-world reality check from a surgeon: on Becker's Healthcare (Sep 12), Mayo Clinic's Dr. Omar Ghanem cited research showing weight-loss surgery delivered an 8.7x reduction in cardiovascular risk with 28% weight loss, versus 1.7x risk reduction and 11% weight loss for GLP-1 medications alone, while noting only about 1% of eligible obesity patients ever get surgery. His point: drugs and surgery may end up as partners, not rivals.

UnitedHealth ($UNH): Cheap for a Reason, or Cheap Enough to Buy?

UNH was the most-discussed insurer, and the tone was cautious-but-warming.

• On Telltales (Sep 14), host Ava Cabot flagged that New York-Presbyterian, the largest hospital system in New York, is set to go out-of-network for most UnitedHealthcare commercial plans on September 30 unless the two sides reach a deal. In the same week, UNH sold an ownership stake in its Florida WellMed clinics to private-equity firm TPG. Her memorable framing: the company is "selling the clinics on one coast, fighting over the hospitals on the other."
• Why the stock is cheap (about 22x free cash flow, among the lowest in the sector): "When your providers are suing you, and the largest hospital system in your biggest market is weeks from walking, the market discounts the cash flow instead of extrapolating it. That's the honest version of cheap."
• The bull case, meanwhile, came from UBS, which reiterated a Buy and a $490 price target on Sep 14 (shares were around $384). UBS said UNH's earnings outlook is "unlikely to change" despite investor nerves about upcoming Medicare Advantage "Stars" quality ratings, and that management is comfortable delivering mid-teens percentage earnings growth per year. Helping sentiment: UNH's medical cost ratio (the share of premiums paid out in claims) improved to 86.7% last quarter from 89.4% a year earlier.

Biotech Breakouts: Cancer Vaccines and Gene Therapy

The rally's poster children were two cancer breakthroughs. Moderna showed its personalized mRNA melanoma vaccine kept cancer from returning or spreading in high-risk patients, and Revolution Medicines won FDA approval for a pancreatic cancer treatment. On WSJ's Take, Wehner said the Moderna news alone added $25–30 billion in market value to a company worth about $20 billion beforehand, which is exactly why he urged caution about how much future success is already priced in.

Gene therapy also had a strong run: Ultragenyx ($RARE) won FDA approval for a gene therapy (Fayuvi) for the rare childhood disease Sanfilippo syndrome, one of a string of recent gene-therapy approvals.

Key Debates: Bull vs. Bear

Debate 1: Is the healthcare rotation a genuine new leadership trade, or just tourists fleeing expensive tech?

• Bull: Empower's Marta Norton called healthcare the "anti-AI trade": cheap, defensive, and largely insulated from a tech sell-off. With inflation still around 3.4% and bond yields near 5%, big pharma and managed care are where nervous money is hiding, and the sector has moved from "cooling off" into "early accumulation."
• Bear: The move is partly just a valuation-driven rotation, and the most exciting biotech names have already run hard. As David Wehner warned on WSJ's Take, breakthrough stocks like Moderna may have gotten "out over their skis": the market is "attributing huge future" value to platforms that still have to prove themselves across many diseases.

Debate 2: Are drug makers overpaying for pipelines they can't value yet?

This was the sharpest disagreement of the week, laid out on Telltales. One half of healthcare is paying 33 to 50 times free cash flow for assets still stuck in clinical trials (Vertex at ~33x, Eli Lilly at ~50x), while the other half, insurers, trades in the teens on cash they already collect.

• Bull: You pay up for optionality. Vertex just posted data showing an experimental therapy restored patients' own insulin production in type 1 diabetes, and Goldman Sachs promptly put it on its conviction list with a $653 target. If these pipelines convert, today's price looks cheap.
• Bear: "Both of these companies are buying revenue that doesn't exist yet, and the memo is already paying full price for it," as co-host Marcus Graham put it. A closed acquisition and a mid-stage trial result "are both promises," and the market is "pricing them like they already cleared."

Debate 3: Twist Bioscience, great technology, wrong price?

• Bull: Twist prints custom DNA on a silicon chip (think computer-chip manufacturing, but for genes), and it's riding the AI-drug-discovery boom. Its therapeutics business grew 49% year-over-year to $40.4 million last quarter, and it even makes proteins that AI company Anthropic designed, a real-world stamp of approval. Bulls see revenue potentially reaching $920 million by 2031.
• Bear: After the stock's big run, the hosts of Chip Stock Investor said they're "still not buying," worried about shareholder dilution (the company keeps issuing new shares) and reliance on a single unnamed supplier for the critical component of its DNA-printing process. Great science, they argued, isn't automatically a great stock at this price.

Emerging Themes

AI is becoming a healthcare story, not just a tech story. Several podcasts made the same point from different angles: the AI trade and the healthcare trade are merging. Drug makers are using AI to design medicines faster, and the "picks-and-shovels" companies that supply the data and materials are benefiting. On Motley Fool Hidden Gems (Sep 14), healthcare investor Rachel highlighted Moderna's AI system (Maestro) for designing cancer vaccines with Merck, and flagged that research-services firms (contract research organizations like Medpace and IQVIA) could be disrupted by AI-accelerated drug discovery, a threat to some, a tailwind to the tech-savvy ones. And Eli Lilly spent the week signing up partners (Twist Bioscience and Ginkgo Bioworks) for TuneLab, its platform that lets outside biotechs tap AI models trained on decades of Lilly's own research data.

"Grounding" AI in real biology. On Data in Biotech (Sep 17), DrugBank CEO Lisa Downey made a sharp point: general-purpose AI chatbots are unreliable for drug research (in one test a model named only 3 approved drugs for a target when the real answer was 6). Her company sells a curated map of drugs, targets and diseases (156 million structured data points used by 9 of the top 20 global pharma companies) to make AI answers accurate. The theme: in medicine, the value is in trustworthy data, not the model.

China is becoming pharma's new idea factory. On Big Take Asia (Sep 15) and BioCentury, the same trend surfaced: Western drug giants that are "no longer really good at innovating" (Wehner's phrase) are increasingly licensing early-stage drugs from Chinese biotechs. BioCentury's Lauren Wallis noted China licensing deals have grown to roughly match Europe as a source, though this raises geopolitical questions the industry is still working through.

The weight-loss wave is now a whole economy. Beyond the stocks, GLP-1 drugs have become a cultural and consumer phenomenon. On The a16z Show (Sep 15), the discussion cited that about 11% of U.S. adults are now on a GLP-1 drug while 90% have heard of them, a massive gap between awareness and adoption that suggests the market still has room to grow, and ripple effects across food, fitness and retail.

Deals & M&A Tracker

Dealmaking was unusually busy, and the appetite for risk is clearly rising.

• Vertex Pharmaceuticals → Kernetics Pharmaceuticals, $8.8 billion (closed Sep 5). The largest acquisition in Vertex's history (via Telltales, Sep 14).
• Eli Lilly → AtaiBeckley, ~$2.8 billion ($6.75/share, closed Sep 11). A clinical-stage company developing fast-acting mental-health treatments; lead program BPL-003 for treatment-resistant depression (thefly, Sep 11; Telltales, Sep 14).
• UnitedHealth (Optum) → sold Florida WellMed clinics stake to TPG (private equity). Shares dipped ~1.8% on the news (MT Newswires, Sep 9).
• Waystar ($WAY) exploring a sale. RBC Capital's Ryan Halsted named Oracle as the "obvious first name," followed by UnitedHealth's Optum, while cautioning Optum "could face regulatory scrutiny." WAY jumped ~8% (thefly, Sep 15).
• Thermo Fisher → Clario (closed March). CEO Marc Casper said it's "performing great" and signaled more M&A is coming, on Squawk on the Street (Sep 15).
• CVS + Cigna → "Cigna Health Works" joint product. Routes Cigna-administered benefits into CVS pharmacies and MinuteClinics, struck the same week CVS was sued by hospitals over the 340B drug-discount program (Telltales, Sep 14).
• Deal backdrop: BioCentury counted 221 deals among the top 21 pharma companies over 12 months, with rising interest in cutting-edge drug types (bispecific antibodies, siRNA). Morgan Stanley's M&A co-head, on Squawk, noted healthcare deal volumes ran near $21 billion annualized even "without very large deals," implying the door is open for something bigger.

Regulatory Watch

Drug tariffs are the sleeping giant. A new 100% tariff on patented, imported drugs (under a trade rule called Section 232) takes full effect for smaller manufacturers on September 29, 2026. Big pharma mostly negotiated their way to 0% by promising to build in the U.S.; the UK also got 0%, while the EU, Japan, South Korea and Switzerland face a preferential 15%. The squeeze falls hardest on roughly 450 mid-sized biotechs. Generic drugs get a two-year grace period, then face 100% in 2028 and 200% in 2029, a setup the industry warns could require $15–25 billion in new U.S. factory spending to avoid 30–50% price hikes.

Medicare price negotiations are biting Novo. The second round of Medicare drug-price negotiations takes effect January 1, 2027, and it includes Novo's Ozempic, Rybelsus and Wegovy. The negotiated 30-day price is a 71% cut, from $959 (2024) down to $274. That's a direct hit to Novo's U.S. pricing power and part of why the stock trades at a discount.

Managed care got a friendlier rate. The government's final 2027 Medicare Advantage rate came in at a net +4.98% (about $26 billion), much better than the +0.09% first proposed, a tailwind for insurers like UnitedHealth and Humana. Offsetting it: the out-of-pocket cap for Part D drug plans rises to $2,400, and a temporary premium subsidy expires at the end of 2026.

FDA green lights kept coming. Ultragenyx's gene therapy for Sanfilippo syndrome was approved ahead of its Sep 19 deadline. GSK posted strong late-stage lung-cancer data (a 94% response rate in one ROS1-positive study). And the comment period for CMS's 2028 drug-pricing guidance closed September 18.

The Week Ahead: What to Watch

• September 19, Ultragenyx ($RARE) PDUFA date already cleared with the Sanfilippo gene-therapy approval; watch the commercial rollout and any read-through to other rare-disease names.
• September 29, Section 232 pharma tariffs hit smaller manufacturers. Watch mid-cap biotech and generic-drug names for compliance updates and any guidance changes.
• September 30, UnitedHealth vs. New York-Presbyterian contract deadline. A deal keeps the network intact; a breakdown is a headline risk. As Telltales put it, "What settles it is the network contract, not the multiple."
• Medicare Advantage "Stars" quality data for payment year 2028, a key swing factor for UNH and peers that investors are watching nervously.
• Novo Nordisk's CagriSema, FDA decision pending. After the head-to-head miss, approval terms and labeling matter for how Novo competes with Lilly.
• Viking Therapeutics (VK2735), topline data from its Phase 3 VANQUISH-2 diabetes trial is expected in Q3 2026 (i.e., imminently), a key test for the leading "third player" in weight loss.
• Ongoing: pharma dealmaking. With Thermo Fisher, Vertex and Lilly all active and Morgan Stanley flagging room for a bigger transaction, another sizable acquisition would not be a surprise.